

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/664,817	0/664,817 09/17/2003		Barry Reisberg	1049-1-034N	3446
23565	7590	06/15/2005	EXAMINER		NER
KLAUBER & JACKSON 411 HACKENSACK AVENUE				ROYDS, LESLIE A	
HACKENSACK, NJ 07601				ART UNIT	PAPER NUMBER
				1614	

DATE MAILED: 06/15/2005

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO.I CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR I PATENT IN REEXAMINATION		ATTORNEY DOCKET NO.
,				
				EXAMINER
			ART UNIT	PAPER
				06132005
			DATE MAILER	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

See attached Interview Summary.

	Application No.	Applicant(s)
Examiner-Initiated Interview Summary	10/664,817	REISBERG, BARRY
Examiner-initiated interview Summary	Examiner	Art Unit
	Leslie A. Royds	1614
All Participants:	Status of Application: Per	nding
(1) Leslie A. Royds.	(3)	
(2) <u>Veronica Mallon</u> .	(4)	
Date of Interview: <u>13 June 2005</u>	Time: <u><i>PM</i></u>	
Type of Interview: ☐ Telephonic ☐ Video Conference ☐ Personal (Copy given to: ☐ Applicant Exhibit Shown or Demonstrated: ☐ Yes ☐ No If Yes, provide a brief description:	nt's representative)	
Part I.		
Rejection(s) discussed: None.		
Claims discussed: None.		
Prior art documents discussed: None.		
Part II.		
SUBSTANCE OF INTERVIEW DESCRIBING THE GENER See Continuation Sheet	RAL NATURE OF WHAT WAS	DISCUSSED:
Part III.		
 It is not necessary for applicant to provide a separate redirectly resulted in the allowance of the application. The of the interview in the Notice of Allowability. It is not necessary for applicant to provide a separate redid not result in resolution of all issues. A brief summary 	examiner will provide a writte ecord of the substance of the	in summary of the substance interview, since the interview
•		
21/1/10		
(Examiner/SPE Signature) (Applicant)	Applicant's Representative Sig	nature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: Ms. Mallon called to inquire how to properly respond to the written restriction requirement and the supplemental election of an agent of group C and the election of a combination of agents as discussed in the telephone conversation on 7 June 2005, because the agents of group C (those of claims 28 and 61) were not presented in the previous requirement and, thus, were not assigned group numbers. Examiner told Ms. Mallon to number the agents appearing in Claim 28 consecutively starting with the number XXII for memantine through number XXXI for dexanabinol and to respond giving both the agent name and the group number assigned.